جستجوی مقالات مرتبط با کلیدواژه "pomalidomide" در نشریات گروه "پزشکی"

Parkinson’s disease (PD) is the second most common neurodegenerative disorder of aging that no effective treatment for this disease has been identified so far. This study aimed to evaluate the therapeutic effects of human endometrial stem cells with pomalidomide as an anti-inflammatory drug on Oxygen reactive species (ROS), C-reactive protein (CRP) and extracellular signal-regulated kinase (ERK) gene expression.

Forty male rats were randomly divided into 5 groups (8 animals in each group) control, Parkinson's and 3 experimental Parkinson's groups receiving stem cells (100,000 cells), pomalidomide (4mg/kg/day) and a combination of stem cells and pomalidomide. Induction of Parkinson's disease was performed by injection of 6-hydroxy dopamine (concentration 6 μg) in the striatum by stereotaxic method. At the end of day 28 after treatment, blood samples were prepared from all groups and the desired factors were measured and statistically analyzed.

The results showed a significant decrease in ROS, CRP and ERK gene expression in the treated groups compared with the Parkinson's group (P <0.05). Also, the comparison of the mentioned factors between the control group and Parkinson's group showed a significant increase in Parkinson's group (P <0.05).

Considering the improvement of the measured factors in Parkinson's rats, allogeneic stem cells can be used as a potential source in future research along with pomalidomide for the treatment of Parkinson's disease.

Allergic asthma is an inflammatory disease of the respiratory system which causes an increase in inflammatory factors such as IL-2,IL-4,IL-5, lymphocytes and eosinophils. These factors can increase the level of free radicals and oxidants. Pomalidumide, an anti-inflammatory drug that has stronger effects than its analogues, can significantly reduce inflammatory factors. The aim of this study was to evaluate the effect of pomalidumide on inflammatory factors and pro-oxidant antioxidant balance in the rat model of ovalbumin-induced asthma. Male rats were divided into 5 groups (n=8): normal saline, ovalbumin+normal saline, ovalbumin+dexamethasone, ovalbumin+pomalidimide (0.4 0.8 mg/kg, ip). We used ELISA method to determine the level of inflammatory factors. We measured pro-oxidant-antioxidant balance (PAB) for assessment of blood oxidant level. We found significant decrease in the levels of inflammatory factors in the pomalidumide group. This decrease was more significant in the group that received pomalidumide 0.8 mg/kg, ip. The results of this study showed that pomalidomide prevented the pro-oxidant antioxidant balance shift towards increasing oxidant factors in the asthmatic rats. Also it prevented increase in inflammatory factors including IL-2, IL-4,IL-5, lymphocytes and eosinophils in the ovalbumin-induced asthma rat model.

Pomalidomide - a combination of Lenalidomide and Thalidomide drugs- is one of the newest anticancer drugs. Pomalidomide induces apoptosis in cancer cells. Furthermore, few studies indicating its relatively low cytotoxic effects on normal peripheral blood cells have been carried out. However, there is yet no information about the effects of Pomalidomide on bone marrow cells that contain important immune cells. In this study, the effect of Pomalidomide on normal bone marrow mononuclear cells was studied. The samples obtained from individuals who clinically needed bone marrow examination, but finally were diagnosed with no serious pathologic conditions in their leukocytes. Remained bone marrow aspirates were obtained and mononuclear cells were isolated. Half of the mononuclear cells were cultured with Pomalidomide (final concentration 10ìM) and the remaining half(control group) were cultured with media alone. After 48h incubation, vital activity (MTT) and cell apoptosis induction rates were assessed. The results showed that the vital activity of bone marrow mononuclear cells cultured in the presence of Pomalidomide increased significantly compared to the control group (P<0.05). However, Pomalidomide had no apoptosis induction and the rate of apoptotic cells had no significant difference with control group. Pomalidomide moderately stimulates the viability (or activity) of normal bone marrow mononuclear cells to improve and maintain them. Also, unlike most anticancer drugs it has no observable toxic effect or apoptosis induction on these cells. So, it may be concluded that Pomalidomide may be more favorable in preventing the side effects of anticancer drugs on normal cells.